Results 21 to 30 of about 12,023 (229)

Cabergoline in the Treatment of Male Orgasmic Disorder—A Retrospective Pilot Analysis

open access: yesSexual Medicine, 2016
Introduction: Male orgasmic disorder is common, with few treatment options. Cabergoline is a dopamine agonist that acts centrally to normalize serum prolactin that could improve orgasmic dysfunction.
Adam B. Hollander, MD   +6 more
doaj   +1 more source

Simultaneous pyometra and viable puppies’ gestation in a bitch [PDF]

open access: yes, 2014
Here we describe a case of pyometra coexisting with gestation in a 4.5 year-old miniature short-haired Dachshund. The dog exhibited depression, vaginal discharge, polydipsia and dehydration. Ultrasound examination revealed the presence of low to moderate
Corrada, Yanina Alejandra   +2 more
core   +5 more sources

Cabergoline therapy for Macroprolactinoma during pregnancy: A case report

open access: yesBMC Research Notes, 2012
Background We assessed the safety of Cabergoline therapy during pregnancy in a lady with hyperprolactinemia intolerant to Bromocriptine. Case presentation We report the case of a 31 year old lady who presented to us with uncontrolled hyperprolactinemia ...
Shahzad Hira   +2 more
doaj   +1 more source

Canine pseudopregnancy: an evaluation of prevalence and current treatment protocols in the UK [PDF]

open access: yes, 2018
Background: There is a dearth of literature on pseudopregnancy in the bitch, with only a few treatment-based studies published since the 1990s. Pseudopregnancy may be under-recognised in bitches and may account for a proportion of behavioural cases ...
A Bastan   +38 more
core   +1 more source

Evaluation of a 5-year programme to prevent mother-to-child transmission of HIV infection in Northern Uganda [PDF]

open access: yes, 2010
Prevention of mother-to-child transmission (PMTCT) is essential in HIV/AIDS control. We analysed 2000-05 data from mother-infant pairs in our PMTCT programme in rural Uganda, examining programme utilization and outcomes, HIV transmission rates and ...
Ahoua, Laurence   +9 more
core   +2 more sources

Uso de lanreotida en combinación con cabergolina o pegvisomant en la práctica clínica en pacientes con acromegalia: el estudio ACROCOMB [PDF]

open access: yes, 2016
[Abstract] PURPOSE: To describe real-world use of lanreotide combination therapy for acromegaly. PATIENTS AND METHODS: ACROCOMB is a retrospective observational Spanish study of patients with active acromegaly treated with lanreotide combination therapy
Bernabéu, Ignacio   +18 more
core   +2 more sources

Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma

open access: yesIndian Journal of Endocrinology and Metabolism, 2017
Background: Clinical relevance of association of cabergoline use for hyperprolactinemia and cardiac valvulopathy remains unclear. Objective: The aim of the study was to determine the prevalence of valvular heart abnormalities in patients taking ...
Shruti Khare   +6 more
doaj   +1 more source

Advances in the treatment of prolactinomas [PDF]

open access: yes, 2006
Prolactinomas account for approximately 40% of all pituitary adenomas and are an important cause of hypogonadism and infertility. The ultimate goal of therapy for prolactinomas is restoration or achievement of eugonadism through the normalization of ...
1997 Data on file   +627 more
core   +1 more source

Comparative efficacy and safety of generic (Bergolak) vs. brand cabergoline in the treatment of patients with prolactin-secreting tumors

open access: yesОжирение и метаболизм, 2015
Objective: To evaluate the effectiveness and safety of cabergoline drug Bergolak («Veropharm», Russia) in the treatment of patients with prolactin-secreting tumors.Materials and methods: The study included 14 patients (14 women, mean age 46±12) diagnosed
Galina Afanas'evna Melnichenko   +3 more
doaj   +1 more source

Long-term Effects of Cabergoline and Levodopa in Japanese Patients with Early Parkinson’s Disease: A 5-Year Prospective Study [PDF]

open access: yes, 2012
Several international studies have suggested that treatment of early Parkinsonʼs disease (PD) with a dopamine agonist instead of levodopa delays the occurrence of motor complications.
Cabergoline as the Starting Treatment and its Long-term Effects (CASTLE) Study Group,   +1 more
core   +1 more source

Home - About - Disclaimer - Privacy